In 1998, the Symposium on the Uncoupling Proteins (UCPs) and Obesity, also held in Quebec City, was centered on newly discovered, exciting UCPs (especially UCP2) and their potential as targets for drug development. Eleven years later, although we are now confronted with the fact that far more complex roles can be assigned to UCP2-4, the recent observation of functional brown adipose tissue (BAT) depots in humans has brought the original UCP (UCP1, formerly known as thermogenin) back at the center of interest in body weight regulation. In the present Symposium, an impressive panel of outstanding scientists have highlighted how novel molecular and genetic tools have led to a completely redefined view of human BAT and energy expenditure.
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Dr Tim Bartness began the afternoon session on the Physiology of BAT Thermogenesis by addressing the neuronal drives that modulate BAT activity. Using viruses with fluorescent markers, he elegantly showed a back-and-forth connection between specific brain regions and interscapular BAT in rodents. Interestingly, the sympathetic nervous system (SNS) is the major if not the only contributor to such a connection, as evidence of parasympathetic nervous system (for example, measurable acetylcholine concentrations or vesicular acetylcholine transporter immunoreactivity) is absent in this depot. Again, using sensory-specific viruses, Bartness also highlighted important circuits between specific brain regions and BAT by sensory nerves, which can apparently be blocked by capsaicin. This entirely novel area of research is challenging but very promising; in particular, important questions such as whether this circuit is part of the SNS regulatory mechanism or functions independently to control other functions (for example, the metabolic status of the tissue on active substrate utilization) remain to be answered.
The second talk of the session was presented by Dr Sven Enerbäck, who first briefly described his previous work on the mesenchyme forkhead 1 (Foxc2) transcription factor in BAT to illustrate the complexity of BAT genesis and functionality. Even though the presence of BAT in newborn infants was described many years ago, the fact that only scarce traces have been observable in adults until recently has impeded the development of a large research effort by the scientific community. Enerbäck summarized the breakthrough discovery of significant BAT depots in adult humans, which changed the view from an almost exclusively animal-restricted field of interest into a possible therapeutic target for human metabolic diseases, especially obesity. Enerbäck postulated that even small changes in BAT-driven energy expenditure could affect body energy balance. However, because functional studies on human BAT are obviously lacking, the factors that can trigger mobilization and switch human BAT into an energy-burning machinery remain unknown. The well-established failure of specific b3-adrenergic agonists (which stimulate BAT activity in rodents) to decrease body weight in human subjects highlights the importance of conducting major studies on the mechanisms that control human BAT stimulation.
The second part of the session addressed the issue of how to integrate the novel data on human BAT into the classical views on body weight regulation, especially on the energy expenditure side of the balance. Dr Michael Rosenbaum presented data from his laboratory that are consistent with the scientific consensus about the powerful drive that leads to weight regain after significant weight loss. After pointing out that skeletal muscle is the major contributor to energy expenditure in humans, Rosenbaum described the behavioral, neuroendocrine and autonomic modifications due to weight loss that are part of an adaptive and coordinated response to increase energy accumulation. Rosenbaum indicated that the reduction in circulating leptin levels is in large part responsible for weight regain, deeply affecting not only food intake but also leading to a 20-25% decline in energy expenditure. Stressing the importance of recognizing that the body opposes any attempts to induce weight loss, he hypothesized that the diminution in blood thyroid hormone concentrations associated with weight loss could as well affect BAT activity and UCP1 expression, which is strongly under the control of these hormones, at least based on extrapolation from rodent studies. Supplementation of thyroid hormone mimetics in the presence of SNS modulators to maintain the SNS drive constant could thus represent an interesting approach to study human BAT biology.
Dr Jan Nedergaard offered an overarching view of the concept that BAT mediates all activities encompassing adaptive thermogenesis, including diet-induced thermogenesis. As the majority of mouse studies on the impact of gene invalidation on thermogenesis are performed at ambient temperature, under which BAT is readily activated, Nedergaard raised the concern that many potentially significant findings are overlooked or misinterpreted. Interestingly, Nedergaard presented work in mice that supported Rosenbaum's data on the importance of leptin in the regulation of energy expenditure, especially with regard to its dependence on UCP1 to induce weight loss beyond the effects on food intake. This is relevant for future studies on the potential of human BAT as a target tissue for weightreducing drugs, as UCP1 activity is not absolutely necessary for other processes such as cold-induced thermogenesis or fever. Thus, because the presence and induction of UCP1 is central to the concept of weight reduction at thermoneutrality, research on the regulation of its expression and activity in human BAT is mandatory. The current lack of information on this topic might explain, for example, why there is no consensual reason behind the failure of b3-adrenergic agonists to induce weight loss in obese patients, despite the established expression of b3-adrenergic receptors in humans.
The findings presented during the afternoon session obviously raise several questions, among which the search for mechanisms to trigger and stimulate the activity of BAT in humans as a means of inducing weight loss is central. Perhaps even more intriguing is the possibility of integrating the novel notions on brown adipocyte differentiation to induce the formation of BAT depots that would have a significant effect on energy balance in an obese individual. However, as pointed out, because skeletal muscle is an important contributor to energy expenditure, the genesis of new adipomyocytes (brown adipocytes in classic depots with the same cellular origin as myocytes) will hopefully not come at the expense of muscle cell differentiation. Research on these topics, among several others, should generate ideas and discoveries of potential new targets for the development of therapeutic agents against the metabolic syndrome. This symposium is a testimony to how the discovery of BAT in adult humans has already invigorated research in this field, which should be greatly appreciated by the many pioneers invited here to present their work.
